

Anti-Emetic Agents Akynzeo (fosnetupitant-palonosetron) J1454 Prior Authorization Request

Medicare Part B Form

Instructions: * Indicates required information – Form may be returned if required information is not provided. Please fax this request to the appropriate fax number listed at the bottom of the page.

	□ Standard Request– (72 Hours)			Urgent Request (standard time frame could place the member's life, health or ability in serious jeopardy)					
	Date Requested								
		r Clinic name:			Phone		/ Fax		
MEMBER INFORMATION									
*Name: *ID#: *DOB:									
PRESCRIBER INFORMATION									
*Name:									
			*Fax:						
*Address: *Fax: DISPENSING PROVIDER / ADMINISTRATION INFORMATION									
			Phone:						
*Address: Fax: PROCEDURE / PRODUCT INFORMATION									
								End Date if	
НС	PC Code	Name of Drug	Dos	e (Wt:	kg Ht:)	Frequency	known	
					<u>_</u>				
□ Self-administered □ Provider-administered □ Home Infusion									
Chart notes attached. Other important information:									
Diagnosis: ICD10: Description:									
□ Provider attests the diagnosis provided is an FDA-Approved indication for this drug									
CLINICAL INFORMATION									
 New Start or Initial Request: (Clinical documentation required for all requests) Provider has reviewed the attached "Criteria for Approval" and attests the member meets ALL required PA criteria. If not, please provide clinical rationale for formulary exception: 									
□ Continuation Requests: (Clinical documentation required for all requests)									
□ Patient had an <u>adequate response</u> or <u>significant improvement</u> while on this medication.									
If not, please provide clinical rationale for continuing this medication:									
ACKNOWLEDGEMENT									
Request By (Signature Required):									



Prior Authorization Group – Anti-Emetic Agents PA

Drug Name(s): AKYNZEO FOSNETUPITANT-PALONOSETRON

Criteria for approval of Prior Authorization Drug:

- 1. Prescribed for an approved FDA diagnosis (as listed below):
- 2. Member does not have any clinically relevant contraindications, or CMS/Plan exclusions, to the requested drug.
- If the member meets all these criteria, they may be approved by the Plan for the requested drug.
- Quantity limits and Tiering will be determined by the Plan.

Exclusion Criteria: N/A

Prescriber Restrictions: N/A

Coverage Duration: Approval will be for 12 months

FDA Indications:

Akynzeo

• Chemotherapy-induced nausea and vomiting, Acute and delayed, associated with highly emetogenic chemotherapy, in combination with dexamethasone; Prophylaxis

Off-Label Uses:

N/A

Age Restrictions:

Safety and efficacy have not been established in patients younger than 18 years

Other Clinical Considerations: N/A

Resources:

https://www.micromedexsolutions.com/micromedex2/librarian/CS/082AA0/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYN C/E2E20C/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.DoIntegrat edSearch?SearchTerm=Octreotide&UserSearchTerm=Octreotide&SearchFilter=filterNone&navitem=searchGlobal#